Clinical Trial Protocol Against Cancer Therapy Side Effects
(Mucositis) Approved
MELBOURNE, Australia (Business Wire EON/PRWEB ) September 2, 2008 --
Anadis Ltd. (ASX:ANX; OTC:ANDIY) an Australian biopharmaceutical company
specializing in oral immunotherapy using naturally derived antibodies
and other proteins is announcing the clinical protocol for its
Cancer-related Mucositis Program was cleared by the Tel Aviv Souraski
Medical Center’s Institutional Review Board
(IRB) and by the Israeli Ministry of Health (MOH). This enables the
initiation of the clinical trial addressing this significant target at
the medical center within a month.
Mucositis is a significant side effect in cancer therapy (between 20%
and 100% of patients, depending on the type of cancer and treatment). It
is characterized by intestinal tissue destruction throughout the GI
tract, including painful mouth ulcerations and severe gastrointestinal
symptoms interfering with nutrition and treatment. There are currently
no effective treatments for GI Mucositis available in the marketplace
and treatment for Oral Mucositis is very expensive and limited to a
narrow group of eligible patients. In the U.S. alone there are more than
10 million patients undergoing cancer treatments and 1.5 million new
cancer cases each year.
The intended product, primarily for the oncology market, will leverage a
unique formulation of Anadis' immune milk-derived anti LPS antibodies,
growth factors and other bioactives combined and delivered using Anadis’
patented oral delivery technology. Anadis anticipates a commercial
product could reach the market within 2-3 years, due to the product’s
excellent safety profile.
Anadis recently announced the receiving a significant grant (see “Anadis
Awarded VISTECH grant for Clinical Trial of Polyclonal Antibodies for
the Treatment of Cancer Related Mucositis”
July 1, 2008) to help fund this important program.
Anadis Limited (ASX: ANX; OTC: ANDIY) is a biopharmaceutical company
focused on antigen-primed, dairy-derived health products. Anadis’
proprietary technology enables rapid development of polyclonal antibody
and other proteins-based solutions to a range of important diseases. The
all-natural colostrum-derived platform, its high safety profile when
administered orally and the proprietary methods of manufacturing, allows
for short time-frame from bench to market with high manufacturing
scalability.
Keyword Tags: antibodies, cancer, milk, mucositis, oncology,
polyclonal antibody
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SW5zZS1aZXRhLUhvcnItVGhpci1QaWdnLVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.